AGIO — AGIOS PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1439222 ·
Last close
$33.08
Market Cap
$1.97B
52W High
$36.35
52W Low
$24.29
ADV30
900,727
Next earnings
2026-07-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 20,746,000 | 19,427,000 | -110,025,000 | -99,111,000 | 1,184,990,000 | 113,600,000 | 75,875,000 |
| Dec 2025 | 19,967,000 | 18,088,000 | -121,578,000 | -108,039,000 | 1,297,225,000 | 89,130,000 | 104,111,000 |
| Sep 2025 | 12,880,000 | 11,201,000 | -116,869,000 | -103,433,000 | 1,385,705,000 | 92,710,000 | 101,375,000 |
| Jun 2025 | 12,455,000 | 10,753,000 | -127,056,000 | -112,020,000 | 1,471,237,000 | 80,871,000 | 101,682,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-380,408,000
Investing CF
$405,909,000
Financing CF
$9,135,000
CapEx
$-14,319,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$11.20
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-802,486,000
Inventory
$35,087,000
Receivables
$10,577,000
ST Investments
$765,295,000
EBIT TTM
$-475,528,000
Pretax Income TTM
$-423,619,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$66,048,000
EBITDA
$-470,265,984
Free Cash Flow
$-267,222,000
Enterprise Value
$1,192,283,008
Total Cash
$737,038,016
Total Debt
$35,745,000
Shares Out
59,471,609
Trailing EPS
$-7.26
Book Value
$18.69
ROE
-32.8%
ROA
-21.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 54,028,000 | -472,132,000 | -412,781,000 | 1,297,225,000 | 104,111,000 | — | -372,977,000 |
| Dec 2024 | 36,498,000 | -425,737,000 | 673,725,000 | 1,663,199,000 | 122,243,000 | — | -389,841,000 |
| Dec 2023 | 26,823,000 | -391,487,000 | -352,088,000 | 937,118,000 | 126,099,000 | — | -296,062,000 |
| Dec 2022 | 14,240,000 | -389,047,000 | -231,801,000 | 1,238,718,000 | 137,904,000 | — | -309,478,000 |
TTM Snapshot
Revenues TTM
$19,879,000
NetIncome TTM
$686,078,000
OpCashFlow TTM
$0
Assets (Latest)
$1,663,199,000
Forward EPS
$-4.72
Max Pain — expiry 2027-01-15
max pain strike: $25.00 · spot: $33.08 · call oi: 8 · put oi: 2,282
Expected Move to 2027-01-15:
±$15.60
(47.16%) —
implied range
$17.48 –
$48.68
· ATM straddle on $35.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MBX | MBX Biosciences, Inc. | $1.98B | $41.59 | — |
| HRMY | Harmony Biosciences Holdings, Inc. | $1.96B | $33.77 | — |
| ZLAB | Zai Lab Ltd | $2.01B | $17.88 | — |
| BHVN | Biohaven Ltd. | $2.05B | $13.62 | — |
| STOK | Stoke Therapeutics, Inc. | $1.88B | $30.26 | — |
News headlines (Yahoo Finance, 1h cache)
Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain Miss
2026-06-13 18:05 · Yahoo
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
2026-06-13 13:00 · Yahoo
Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?
2026-06-04 15:30 · Yahoo
How The Tebapivat Setback Is Reframing The Story For Agios Pharmaceuticals (AGIO)
2026-06-03 13:12 · Yahoo
AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate
2026-06-02 14:24 · Yahoo
Agios Pharmaceuticals licenses global rights to Oscotec's SYK inhibitor cevidoplenib
2026-06-01 16:26 · Yahoo
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes
2026-06-01 13:43 · Yahoo
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
2026-06-01 09:00 · Yahoo
Why Is Agios Pharmaceuticals (AGIO) Up 8.6% Since Last Earnings Report?
2026-05-29 15:30 · Yahoo
Agios slides after discontinuing development of tebapivat in myelodysplastic syndromes (AGIO)
2026-05-29 14:26 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.